FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06681 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,266,278,000 | | 0 | | 1,266,278,000 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 1,266,278,000 | | 0 | | 1,266,278,000 | 第 2 頁 共 10 頁 v 1.1.1 公司名稱: 腦動極光醫療科技有限公司（於開曼群 ...

Core Viewpoint - The company announced significant changes in its board of directors, including the resignation of Mr. Li Yuezhong and the appointment of new members, which may impact its governance structure and operational leadership [1] Group 1: Board Changes - Mr. Li Yuezhong has resigned as an independent non-executive director and will no longer serve as the chairman of the remuneration committee, a member of the audit committee, and a member of the nomination committee, effective from November 18, 2025 [1] - Mr. Tu Lei has been appointed as an independent non-executive director, chairman of the remuneration committee, and a member of both the audit committee and the nomination committee, effective from November 18, 2025 [1] - Ms. Li Mingqiu and Mr. Lin Xiaobo have been appointed as members of the nomination committee [1] Group 2: Executive Leadership - The company has appointed Mr. Cai Longjun, the current Chief Technology Officer and Chief Operating Officer, as the new Chief Executive Officer, effective immediately [1]

Group 1 - Mr. Li Yuezhong has resigned as an independent non-executive director due to other work commitments and personal time arrangements, effective from November 18, 2025 [1] - Mr. Tu Lei has been appointed as an independent non-executive director, chairman of the remuneration committee, member of the audit committee, and member of the nomination committee, effective from November 18, 2025 [1] - Ms. Li Mingqiu and Mr. Lin Xiaobo have been appointed as members of the nomination committee [1] Group 2 - The company's Chief Technology Officer and Chief Operating Officer, Mr. Cai Longjun, has been appointed as the Chief Executive Officer, effective immediately [1]

腦動極光醫療科技有限公司（「本公司」）根據本公司董事會（「董事會」）於2024年 12月19日通過的一項決議案成立提名委員會（「委員會」）。下文所載為委員會的職 權範圍。職權範圍可供以中英文版本閱覽。職權範圍的中英版本如有任何歧義， 概以英文版本為準。 （股份代號：6681） 提名委員會的職權範圍 （本公司乃根據於2025年11月18日通過的董事會決議案所採納） BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） 2. 釋義 2.1. 就本職權範圍（「職權範圍」）而言： 董事會指本公司的董事會。 首席財務官指董事會不時委任負責管理財務的本公司高級行政人員。 公司秘書指本公司任何公司秘書。 董事指董事會成員。 本集團指於有關期間，本公司及其附屬公司以及聯營公司；或如文義另 有所指，於本公司成為其現時附屬公司及聯營公司的控股公司前期間， 本公司現時附屬公司及聯營公司或其現時附屬公司及聯營公司或其前身 （視乎情況而定）所營運的業務。 1 1. 目的 1.1. 委員會旨在物色、考慮適當候選人擔任本公司董事，並向董事會提出建 議，監察 ...

Core Viewpoint - Brainstorming Aurora-B (06681.HK) announced the resignation of Li Yuezhong as an independent non-executive director effective November 18, 2025, due to other work commitments and personal time arrangements [1] - The company subsequently appointed Tu Lei as an independent non-executive director effective November 18, 2025 [1] Summary by Category - **Director Changes** - Li Yuezhong has resigned from his position as an independent non-executive director effective November 18, 2025 [1] - Tu Lei has been appointed as the new independent non-executive director effective November 18, 2025 [1]

BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） 獨立非執行董事 林曉波先生 段濤博士 涂雷先生 董事會下設三個委員會。下表詳列該等委員會的成員。 | | 董事會委員會 | 審計 | 薪酬 | 提名 | | --- | --- | --- | --- | --- | | 董事 | | 委員會 | 委員會 | 委員會 | | 譚錚先生 | | – | – | C | | 李思睿先生 | | – | – | – | | 李明秋女士 | – | | – | M | | Deng Feng先生 | | – | – | – | | 林曉波先生 | | C | M | M | | 段濤博士 | | M | M | M | | 涂雷先生 | | M | C | M | 董事名單與其角色及職能 腦動極光醫療科技有限公司（「本公司」）董事會（「董事會」）成員載列如下。 執行董事 譚錚先生 （董事會主席） 非執行董事 李思睿先生 李明秋女士 Deng Feng先生 （股份代號：6681） 附註： C－相關董事會委員會的主席 M－相關董事會委員 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 獨立非執行董事及董事會委員會組成變動 及 委任首席執行官 獨立非執行董事變動 腦動極光醫療科技有限公司（「本公司」，連同其附屬公司，統稱「本集團」）董事 （「董事」）會（「董事會」）宣佈，李月中先生（「李先生」）由於其他工作安排及個人 時間安排，已辭任獨立非執行董事，自2025年11月18日起生效。 李先生已確認其與董事會並無意見分歧，且概無有關其辭任的事宜須敦請本公司 股東或香港聯合交易所有限公司（「聯交所」）垂注。 董事會欣然宣佈，自2025年11月18日起，塗雷先生（「塗先生」）已獲委任為獨立 非執行董事。 1 塗先生的履歷詳情載列如下： 塗雷先生，44歲，在企業融資及企業管理方面擁有豐富經驗。 塗先生於2005年4月至2016年9月在渣 ...

Core Viewpoint - The brain-computer interface (BCI) concept stocks in the Hong Kong market have shown strong performance, driven by the advancement of a domestically developed implantable wireless BCI system entering a special review process by the National Medical Products Administration (NMPA) in China, marking a significant step in the commercialization of this technology [1][2]. Group 1: Market Performance - Brain动极光-B has increased by over 9%, with a latest price of 6.960 and a total market capitalization of 8.813 billion [2] - 微创脑科学 has risen by over 4%, with a latest price of 11.880 and a total market capitalization of 6.843 billion [2] - 南京熊猫电子股份 has gained nearly 3%, with a latest price of 5.140 and a total market capitalization of 4.697 billion [2] Group 2: Industry Development - The implantable wireless brain-computer interface system developed by Shanghai Ladder Medical Technology Co., Ltd. is the first invasive BCI product to enter the "green channel" for innovative medical devices in China, indicating a key transition from clinical validation to market access in this cutting-edge technology field [1]

Core Viewpoint - The brain-machine interface (BMI) sector is experiencing a significant rise, driven by advancements in technology and supportive regulatory developments in China [1] Group 1: Market Performance - Brain-machine concept stocks have collectively surged, with notable increases: Brainhole Aurora (06681) up 8.49% to HKD 6.9, Nanjing Panda Electronics (00553) up 3.2% to HKD 5.16, and Microneuroscience (02172) up 4.39% to HKD 11.9 [1] Group 2: Regulatory Developments - On November 11, Shanghai Ladder Medical Technology Co., Ltd.'s "implantable wireless brain-machine interface system" entered the special review process for innovative medical devices by the National Medical Products Administration (NMPA), marking it as the first invasive brain-machine interface product to enter this "green channel" in China [1] - The NMPA has also released the YY/T 1987—2025 standard for medical devices utilizing brain-machine interface technology, indicating a formalization of industry standards [1] Group 3: Industry Outlook - Dongwu Securities expresses optimism regarding the domestic policy support and accelerated clinical and commercial progress in the brain-machine interface industry [1] - Huafu Securities notes that advancements in brain science, artificial intelligence, medicine, cognitive neuroscience, and psychology are enriching the scope of brain-machine interfaces, highlighting multiple advantages for the development of this industry in China [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 腦動極光醫療科技有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06681 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000,000 USD | | 0.0000001 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 500,000,000,000 USD | | 0.0000001 | USD | | 50,000 ...